FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR
FRA:4AB (5/23/2025, 7:00:00 PM)
161.2
+1 (+0.62%)
The current stock price of 4AB.DE is 161.2 EUR. In the past month the price increased by 1.77%. In the past year, price increased by 11.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
AMG.DE | AMGEN INC | 13.04 | 128.75B | ||
GIS.DE | GILEAD SCIENCES INC | 13.71 | 116.78B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.52 | 115.05B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 98.47B | ||
ARGX.BR | ARGENX SE | 108.79 | 31.42B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.65B | ||
IDP.DE | BIOGEN INC | 7.87 | 16.14B | ||
1BIIB.MI | BIOGEN INC | 7.52 | 16.05B | ||
1MRNA.MI | MODERNA INC | N/A | 8.79B | ||
0QF.DE | MODERNA INC | N/A | 8.78B | ||
BIO.DE | BIOTEST AG | 66.15 | 1.70B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.68B |
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
The current stock price of 4AB.DE is 161.2 EUR. The price increased by 0.62% in the last trading session.
The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.
4AB.DE stock is listed on the Deutsche Boerse Ag exchange.
34 analysts have analysed 4AB.DE and the average price target is 192.03 EUR. This implies a price increase of 19.12% is expected in the next year compared to the current price of 161.2. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABBVIE INC (4AB.DE) has a market capitalization of 284.74B EUR. This makes 4AB.DE a Mega Cap stock.
ABBVIE INC (4AB.DE) currently has 55000 employees.
ABBVIE INC (4AB.DE) has a support level at 153.27 and a resistance level at 161.76. Check the full technical report for a detailed analysis of 4AB.DE support and resistance levels.
The Revenue of ABBVIE INC (4AB.DE) is expected to grow by 6.89% in the next year. Check the estimates tab for more information on the 4AB.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABBVIE INC (4AB.DE) has a dividend yield of 3.59%. The yearly dividend amount is currently 5.53. Check the full fundamental report for a detailed analysis of 4AB.DE dividend history, reliability and sustainability.
ABBVIE INC (4AB.DE) will report earnings on 2025-07-23, before the market open.
The PE ratio for ABBVIE INC (4AB.DE) is 17.75. This is based on the reported non-GAAP earnings per share of 9.08 and the current share price of 161.2 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 4AB.DE.
ChartMill assigns a technical rating of 1 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE is a bad performer in the overall market: 63.37% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. 4AB.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 9.08. The EPS decreased by -6.3% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 7.24% | ||
ROA | 3.05% | ||
ROE | 292.61% | ||
Debt/Equity | 46.56 |
ChartMill assigns a Buy % Consensus number of 80% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of 23.49% and a revenue growth 6.89% for 4AB.DE